Active Ingredient(s): Osimertinib
FDA Approved: * November 13, 2015
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Tagrisso Overview

Osimertinib, sold under the brand name Tagrisso,[3] is a medication used to treat non-small-cell lung carcinomas with specific mutations.[4][5] It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. The most common side effects include diarrhea, rash, musculoskeletal pain, dry skin, skin inflammation around nails, sore mouth, fatigue and cough.[6] Osimertinib was approved for medical use in the Unit...

Read more Tagrisso Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Osimertinib

Recent Tagrisso Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Tablet: 40mg, 80mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Tagrisso: (2 results)

Sorted by National Drug Code
  • 0310-1349 Tagrisso 40 1/1 Oral Tablet, Film Coated by Astrazeneca Pharmaceuticals Lp
  • 0310-1350 Tagrisso 80 1/1 Oral Tablet, Film Coated by Astrazeneca Pharmaceuticals Lp

Other drugs which contain Osimertinib or a similar ingredient: (1 result)